We use high purity Fe oxide nanoparticles to confirm the Fe 2p X-ray photoemission peak attributions made in our previous study of Fe nanoparticles and the initial stage of their oxidation. To accomplish this, we have found it necessary to consider the spectral contributions of the ligand field of the Fe−O crystal structure, the crystalline disorder at the nanoparticle surface, and the Russell−Saunders broadening of the FeIII components of the Fe 2p spectra.
No takes yet. Share an insight, caveat, or question.
Poulin et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: